Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery Patients

Study ID
NCT01320319

Study type
Interventional

Study phase
Phase 2/Phase 3

Study status
Unknown status

Trial Acronym

EPA-colo

Trial Summary

Primary Aim is to test the Hypothesis: Nutritional supplementation with 960mg EPA three times a day positively affects muscle function and mass (assessed by muscle biopsies, assays of cellular aerobic function and DEXA scan) and inflammation (measuring cellular markers of inflammation) in patients undergoing resection of colorectal cancers. The secondary aim is to evaluate aerobic performance assessed by cardiopulmonary exercise testing (CPEX) and perioperative outcome in patients with colorectal cancer post surgical resection.

More informations

Trial Starting Date

Mar 31,2011

Requirements

Gender All
Minimum age 18 Years
Maximum age 85 Years

Enrollement Limit